Scott IV - Search Results

1

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM. Popple A, et al. Among authors: scott iv. Br J Cancer. 2012 Mar 27;106(7):1306-13. doi: 10.1038/bjc.2012.49. Epub 2012 Mar 13. Br J Cancer. 2012. PMID: 22415233 Free PMC article.

2

No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials.

Abdel-Rahman ME, Butler J, Sydes MR, Parmar MK, Gordon E, Harper P, Williams C, Crook A, Sandercock J, Swart AM, Rachet B, Coleman MP; ICON2 and ICON3 investigators. Abdel-Rahman ME, et al. Br J Cancer. 2014 Jul 29;111(3):589-97. doi: 10.1038/bjc.2014.303. Epub 2014 Jun 10. Br J Cancer. 2014. PMID: 24918817 Free PMC article.

3

A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.

Wilson AP, Fox H, Scott IV, Lee H, Dent M, Golding PR. Wilson AP, et al. Among authors: scott iv. Br J Cancer. 1991 Jan;63(1):102-8. doi: 10.1038/bjc.1991.21. Br J Cancer. 1991. PMID: 1989647 Free PMC article.

4

Cytotoxic activity and phenotypic analysis of natural killer cells in early normal human pregnancy.

Lee H, Gregory CD, Rees GB, Scott IV, Golding PR. Lee H, et al. Among authors: scott iv. J Reprod Immunol. 1987 Sep;12(1):35-47. doi: 10.1016/0165-0378(87)90079-9. J Reprod Immunol. 1987. PMID: 3694593

5

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I, Durrant LG. Duncan TJ, et al. Among authors: scott iv. Clin Cancer Res. 2008 May 15;14(10):3030-5. doi: 10.1158/1078-0432.CCR-07-1888. Clin Cancer Res. 2008. PMID: 18483368

6

Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.

Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, Durrant LG. Duncan TJ, et al. Among authors: scott iv. Clin Cancer Res. 2007 Jul 15;13(14):4139-45. doi: 10.1158/1078-0432.CCR-06-2833. Clin Cancer Res. 2007. PMID: 17634541 Clinical Trial.

7

Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.

de Foy KA, Gayther SA, Colledge WH, Crockett S, Scott IV, Evans MJ, Ponder BA. de Foy KA, et al. Among authors: scott iv. Br J Cancer. 1998 May;77(10):1642-4. doi: 10.1038/bjc.1998.269. Br J Cancer. 1998. PMID: 9635841 Free PMC article.

8

Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.

Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA, Gayther SA. Foster KA, et al. Among authors: scott iv. Cancer Res. 1996 Aug 15;56(16):3622-5. Cancer Res. 1996. PMID: 8705994

9

The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer.

Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RC, Wilkinson P, Cruickshank D, McAllister EJ, Redman CW, Parker D, Scott IV, Slevin ML, Roulston JE. Fayers PM, et al. Among authors: scott iv. Int J Gynecol Cancer. 1993 Sep;3(5):285-292. doi: 10.1046/j.1525-1438.1993.03050285.x. Int J Gynecol Cancer. 1993. PMID: 11578359

10

The identification of high risk and practical strategies for a population based randomized trial of ovarian cancer screening.

Scott IV. Scott IV. Dis Markers. 1991 May-Aug;9(3-4):133-52. Dis Markers. 1991. PMID: 1813206 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page